GlobalData Report: Novel Therapies to Revitalize the Neuropathic Pain Treatment Market Landscape by 2022 - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
GlobalData Report: Novel Therapies to Revitalize the Neuropathic Pain Treatment Market Landscape by 2022

Source: Applied Clinical Trials

A new report from research and consulting firm GlobalData forecasts the neuropathic pain (NP)—covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia—market value to increase from $2.58 billion in 2012 to $3.53 billion by 2022, at a compound annual growth rate of 3.19%.

The report cites the expected launch of seven promising NP treatments before 2022—including Daiichi Sankyo’s DS-5565, Convergence’s CNV-2197944, Grünenthal’s Cebranopadol and Impax’s Eladur—and the expected sales of these pipeline therapies to account for 23.8% of the global NP market.

GlobalData believes that there are opportunities for companies to enter the NP market through the development of novel drugs, provided that their product offerings target some of these unmet needs.

*PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here